\
&
Contact us
\
&
Contact us
This was 6 years ago
LocationStadthalle Pollheimerstrasse, 1 4600 Wels Austria |
WSED tackles clean energy transition and its new dynamic in Europe and worldwide where "Energy efficiency first" and "global leadership in renewables" are at the centre of this transformation process. WSED comprises conferences, workshops, technical visits and a trade show.
On 6 March at 11:00 a H2020 Energy Workshop is organised in conjunction with the "European Energy Efficiency Conference" with the aim to get young energy researchers prepared for participation in the last H2020 Energy calls and to provide an outlook to Horizon Europe.
Agenda of the workshop:
Find the direct link to the workshop section of the programme here: http://www.wsed.at/en/programme/european-energy-efficiency-conference.html#c25570
Registration to the workshop: no separate registration is necessary as it is part of the conference. Just add the reference "Participation H2020 Workshop" in the comment field of the online formular when registering for the conference!
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
